MX2010007833A - Compuestos que tienen actividad antagonista de crth2. - Google Patents

Compuestos que tienen actividad antagonista de crth2.

Info

Publication number
MX2010007833A
MX2010007833A MX2010007833A MX2010007833A MX2010007833A MX 2010007833 A MX2010007833 A MX 2010007833A MX 2010007833 A MX2010007833 A MX 2010007833A MX 2010007833 A MX2010007833 A MX 2010007833A MX 2010007833 A MX2010007833 A MX 2010007833A
Authority
MX
Mexico
Prior art keywords
alkyl
compounds
independently
heteroaryl
cycloalkyl
Prior art date
Application number
MX2010007833A
Other languages
English (en)
Inventor
Richard Edward Armer
Graham Michael Wynne
Mark Whittaker
Eric Roy Pettipher
Julia Vile
Frank Schroer
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0800874A external-priority patent/GB0800874D0/en
Priority claimed from GB0820526A external-priority patent/GB0820526D0/en
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Publication of MX2010007833A publication Critical patent/MX2010007833A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Compuestos de Fórmula General (I) en donde W, es cloro o flúor; R1 es fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados de halo, -CN, alquil de 1 a 6 átomos de carbono, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)pOR2, y -O(CH2)pO(CH2)qOR2, en donde cada R2 es independientemente hidrógeno, alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, arilo o heteroarilo; cada R3 es independientemente alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, arilo o heteroarilo; p y q son independientemente entre sí un entero de 1 a 3; y sus sales, hidratos, solvatos, complejos o profármacos aceptables farmacéuticamente son útiles en composiciones administrables oralmente para el tratamiento de enfermedades alérgicas tales como asma, rinitis alérgica y dermatitis atópica. (ver fórmula (I)).
MX2010007833A 2008-01-18 2009-01-19 Compuestos que tienen actividad antagonista de crth2. MX2010007833A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0800874A GB0800874D0 (en) 2008-01-18 2008-01-18 Compounds having CRTH2 antagonist activity
GB0820526A GB0820526D0 (en) 2008-11-10 2008-11-10 Compounds having crth2 antagonist activity
PCT/GB2009/000142 WO2009090414A1 (en) 2008-01-18 2009-01-19 Compounds having crth2 antagonist activity

Publications (1)

Publication Number Publication Date
MX2010007833A true MX2010007833A (es) 2010-08-11

Family

ID=40473418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007833A MX2010007833A (es) 2008-01-18 2009-01-19 Compuestos que tienen actividad antagonista de crth2.

Country Status (25)

Country Link
US (1) US20090186923A1 (es)
EP (1) EP2250161B1 (es)
JP (2) JP2011509988A (es)
KR (1) KR101644170B1 (es)
CN (1) CN101932571B (es)
AU (1) AU2009204700B2 (es)
BR (1) BRPI0906786B1 (es)
CA (1) CA2712017C (es)
CY (1) CY1114748T1 (es)
DK (1) DK2250161T3 (es)
ES (1) ES2442717T3 (es)
HK (1) HK1145175A1 (es)
HR (1) HRP20140045T1 (es)
IL (1) IL206959A (es)
MA (1) MA32075B1 (es)
MX (1) MX2010007833A (es)
MY (1) MY155133A (es)
NZ (1) NZ587251A (es)
PL (1) PL2250161T3 (es)
PT (1) PT2250161E (es)
RS (1) RS53142B (es)
RU (1) RU2503672C2 (es)
SI (1) SI2250161T1 (es)
WO (1) WO2009090414A1 (es)
ZA (1) ZA201005799B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US20100298368A1 (en) * 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
WO2009061676A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
MY155133A (en) * 2008-01-18 2015-09-15 Atopix Therapeutics Ltd Compounds having crth2 antagonist activity
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509990A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
NZ587709A (en) 2008-02-01 2012-06-29 Panmira Pharmaceuticals Llc N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
US8242145B2 (en) * 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) * 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
EP2307362A4 (en) * 2008-07-03 2012-05-09 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
EP2461809A4 (en) * 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
SG178252A1 (en) * 2009-08-05 2012-03-29 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
SG182398A1 (en) 2010-01-06 2012-08-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
RU2562255C2 (ru) 2010-03-22 2015-09-10 Актелион Фармасьютиклз Лтд Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве модуляторов рецепторов простагландина d2
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
KR101928595B1 (ko) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도
CN103958466B (zh) 2011-11-17 2015-11-25 山东亨利医药科技有限责任公司 作为crth2拮抗剂的含氮并环化合物
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
AU2012351342A1 (en) * 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2014009302A1 (en) * 2012-07-10 2014-01-16 F. Hoffmann-La Roche Ag Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
UY35165A (es) 2012-12-04 2014-06-30 Takeda Pharmaceutical Método profiláctico o terapéutico para el síndrome de sjogren
NZ628320A (en) * 2013-03-14 2017-04-28 Celgene Corp Treatment of psoriatic arthritis using apremilast
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
CA2938107A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407807D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407813D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
KR102343802B1 (ko) * 2014-06-09 2021-12-28 수미토모 케미칼 컴퍼니 리미티드 피리딘 화합물의 제조 방법
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
AU2018318075B2 (en) 2017-08-14 2023-04-13 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
JP2022517610A (ja) * 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド 複素環化合物塩およびその使用
CN114796264A (zh) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
IL298984A (en) * 2020-06-12 2023-02-01 Nucmito Pharmaceuticals Co Ltd Indan compounds, their pharmaceutical preparations and their medical applications
AU2022277167A1 (en) * 2021-05-15 2023-11-30 Nucmito Pharmaceuticals Company Limited Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
CN115192584A (zh) * 2022-06-09 2022-10-18 南方科技大学 一种纳米药物及其制备方法和应用
WO2024104384A1 (en) * 2022-11-16 2024-05-23 Nucmito Pharmaceuticals Co. Ltd. Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB1407658A (en) 1973-03-06 1975-09-24 Ici Ltd Process for the manufacture of indole derivatives
GB1460348A (en) 1974-02-04 1977-01-06 Ici Ltd Quinazoline derivativesa
DK151884C (da) 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
WO1997046677A1 (fr) 1996-06-05 1997-12-11 Bml, Inc. PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ATE269861T1 (de) 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
JP3486408B2 (ja) 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
JP2003519898A (ja) 2000-01-14 2003-06-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 表示装置
US6521659B2 (en) 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja) 2000-03-08 2001-09-11 Japan Tobacco Inc インドール酢酸化合物及びその製造方法
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
US7364647B2 (en) 2002-07-17 2008-04-29 Eksigent Technologies Llc Laminated flow device
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
JP4324418B2 (ja) 2003-08-05 2009-09-02 株式会社日立国際電気 基板処理装置および半導体デバイスの製造方法
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
AU2004283139A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
RU2376286C2 (ru) 2004-03-11 2009-12-20 Актелион Фармасьютиклз Лтд Производные индол-1-илуксусной кислоты
BRPI0510043A (pt) * 2004-04-20 2007-10-16 Pfizer método de tratamento de dor neuropática usando antagonista de receptor crth2
KR20070089908A (ko) 2004-09-21 2007-09-04 아더시스 인코포레이티드 Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
PL65781Y1 (pl) 2005-08-16 2012-02-29 Katarzyna Kawczyńska Wkładka kosmetyczna
PL2046740T3 (pl) 2006-07-22 2012-10-31 Oxagen Ltd Związki o aktywności antagonisty CRTH2
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
DK2327693T3 (da) * 2007-12-14 2012-08-13 Pulmagen Therapeutics Asthma Ltd Indoler og terapeutisk anvendelse deraf
MY155133A (en) * 2008-01-18 2015-09-15 Atopix Therapeutics Ltd Compounds having crth2 antagonist activity

Also Published As

Publication number Publication date
AU2009204700A1 (en) 2009-07-23
PL2250161T3 (pl) 2014-05-30
JP5855162B2 (ja) 2016-02-09
MA32075B1 (fr) 2011-02-01
CN101932571A (zh) 2010-12-29
BRPI0906786B1 (pt) 2021-10-05
HRP20140045T1 (hr) 2014-02-14
NZ587251A (en) 2011-12-22
US20090186923A1 (en) 2009-07-23
CA2712017A1 (en) 2009-07-23
KR20100110361A (ko) 2010-10-12
KR101644170B1 (ko) 2016-08-01
CA2712017C (en) 2016-08-09
EP2250161A1 (en) 2010-11-17
RS53142B (en) 2014-06-30
SI2250161T1 (sl) 2014-04-30
AU2009204700B2 (en) 2013-07-04
EP2250161B1 (en) 2013-10-16
JP2014159465A (ja) 2014-09-04
ZA201005799B (en) 2012-01-25
RU2010129027A (ru) 2012-02-27
BRPI0906786A2 (pt) 2015-07-14
DK2250161T3 (da) 2014-01-27
RU2503672C2 (ru) 2014-01-10
JP2011509988A (ja) 2011-03-31
PT2250161E (pt) 2014-01-21
ES2442717T3 (es) 2014-02-13
HK1145175A1 (en) 2011-04-08
MY155133A (en) 2015-09-15
WO2009090414A1 (en) 2009-07-23
CY1114748T1 (el) 2016-12-14
CN101932571B (zh) 2014-04-23
IL206959A (en) 2014-09-30
IL206959A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MX2010007833A (es) Compuestos que tienen actividad antagonista de crth2.
CY1114141T1 (el) Ενωσεις που εχουν ανταγωνιστικη του crth2 δραστηριοτητα
EA201170096A1 (ru) Замещенные производные пиримидона
RS53156B (en) N1-PYRAZOLOSPIROKETONES AS ACETYL-COA CARBOXYLASE INHIBITORS
RS54369B1 (en) NEW QUINOLINE COMPOUNDS SUBSTITUTED AS S-NITROSOGLUTATHION REDUCTASE INHIBITORS
RS54189B1 (en) PROCEDURES FOR USING ALK INIBITORS
ECSP12012212A (es) Derivados de ariletinilo
EA201101297A1 (ru) Аддитивные соли аминов, содержащих гидроксильные и/или карбоксильные группы, с производными аминоникотиновой кислоты в качестве ингибиторов dhodh
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
RS53839B1 (en) SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
RS53342B (en) DERIVATIVES OF PRIVATE AND INHIBITORIES MEK
EA201290909A1 (ru) Химические соединения
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
RS54183B1 (en) PIRAZOLE DERIVATIVES
AU2011209274A8 (en) Substituted naphthyridines and their use as Syk kinase inhibitors
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2597088A4 (en) P2X4 Receptor Antagonists
UA109525C2 (xx) Алкіламідна сполука і її застосування
EA201590684A1 (ru) Новые соединения
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights